-
Clinical trial tests therapy for aggressive B-cell lymphomas
-
Tumor cells in transparent fish reveal factors that determine metastasis sites
-
FDA grants breakthrough therapy designation of new TIL therapy for advanced cervical cancer
-
In patients with severe chronic lymphocytic leukemia, B cells get stuck in hyperactive mode
-
Landmark discovery: H2AX as a sensor of DNA damage
-
One more week to apply for the Lasker #clinicalresearch program. Application deadline is Friday, August 30th. For d… https://t.co/DbFZHDHFoi
-
RT @NCICCR_MOS: At @NCICCR_MOS, & elsewhere @theNCI, we are investigating how precision medicine can help physicians tailor their t… https://t.co/PldwFfP1iI
-
RT @NIHBrainTumor: If you have a rare brain or spine tumor and want to help researchers understand your disease to develop better ther… https://t.co/pzWdjN8uCL
-
#NowHiring Our Surgical Oncology Program @NCICCR_SurgOnc is seeking an experienced professional to develop and impl… https://t.co/TB3h1BkdzH
-
Newest #CCRAdvance from @NCIEytanRuppin Lab published in @JAMAOnc https://t.co/aGMlA3S4yd
-
New #ClinicalTrial of combination therapy for aggressive B-cell #lymphoma being led by @RoschewskiMD… https://t.co/tKVG37ONiL
-
RT @IRPatNIH: The #NIH IRP has a long track record of producing innovations to help improve #flu care and prevention. We recently… https://t.co/eiqVJzOUa1
